{
    "cancer_info": {
        "cancer_name": "Rectal Cancer"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Digital rectal exam (DRE)",
            "Carcinoembryonic antigen (CEA) testing",
            "Pelvic MRI (high-resolution T2-weighted + DWI)",
            "Chest/Abdomen/Pelvis CT with IV contrast",
            "Endoscopic ultrasound (EUS) for early tumors",
            "Colonoscopy ± proctoscopy",
            "Biopsy with histopathologic review",
            "Mismatch repair (MMR)/microsatellite instability (MSI) testing",
            "Broad molecular profiling (KRAS/NRAS, BRAF, HER2, POLE/POLD1, NTRK, RET fusions)",
            "Tumor Mutational Burden (TMB) testing",
            "FDG-PET/CT for equivocal findings",
            "Hepatic MRI for resectable liver metastases"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "T1-2N0",
            "risk_group": "Low Risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Early-stage tumors",
                    "plan_name": "Local excision or resection",
                    "plan_details": "Transanal local excision (for tumors ≤3 cm, well-differentiated, no LVI/PNI) or transabdominal resection followed by observation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard option"
                }
            ]
        },
        {
            "staging_criteria": "T3-4N0 or T1-2N1-2",
            "risk_group": "Locally advanced (pMMR/MSS)",
            "treatment_plans": [
                {
                    "treatment_line": "Neoadjuvant therapy",
                    "patient_subgroup": "Non-metastatic disease",
                    "plan_name": "Total Neoadjuvant Therapy (TNT)",
                    "plan_details": "FOLFOX/CAPEOX × 12-16 weeks → restaging (sigmoidoscopy/MRI). If tumor regression ≥20% → surgery or surveillance; if <20% → long-course chemoradiation (5-FU/capecitabine + 45-50.4 Gy RT) or short-course RT → surgery",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Alternative neoadjuvant",
                    "patient_subgroup": "Non-metastatic disease",
                    "plan_name": "Chemoradiation → surgery → adjuvant chemo",
                    "plan_details": "Long-course chemoradiation → Total Mesorectal Excision (TME) surgery → adjuvant FOLFOX/CAPEOX × 4-6 months",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Alternative option"
                }
            ]
        },
        {
            "staging_criteria": "T3-4N0 or T1-2N1-2",
            "risk_group": "dMMR/MSI-H or POLE/POLD1 mutant (TMB ≥50 mut/Mb)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Mismatch repair deficient",
                    "plan_name": "Checkpoint inhibitors",
                    "plan_details": "Nivolumab ± ipilimumab or pembrolizumab → surgery/surveillance if complete response",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic disease",
            "risk_group": "Resectable metastases (liver/lung)",
            "treatment_plans": [
                {
                    "treatment_line": "Perioperative therapy",
                    "patient_subgroup": "pMMR/MSS",
                    "plan_name": "Neoadjuvant chemotherapy → resection",
                    "plan_details": "FOLFOX/CAPEOX → metastasectomy ± ablation/SBRT",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Perioperative therapy",
                    "patient_subgroup": "dMMR/MSI-H",
                    "plan_name": "Immunotherapy → resection",
                    "plan_details": "Checkpoint inhibitors → metastasectomy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic disease",
            "risk_group": "Unresectable metastases",
            "treatment_plans": [
                {
                    "treatment_line": "First-line systemic therapy",
                    "patient_subgroup": "pMMR/MSS",
                    "plan_name": "FOLFOX/CAPEOX ± biologics",
                    "plan_details": "FOLFOX/CAPEOX ± bevacizumab; add anti-EGFR (cetuximab/panitumumab) for RAS/BRAF wild-type",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line systemic therapy",
                    "patient_subgroup": "dMMR/MSI-H",
                    "plan_name": "Checkpoint inhibitors",
                    "plan_details": "Pembrolizumab or nivolumab ± ipilimumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line systemic therapy",
                    "patient_subgroup": "BRAF V600E mutant",
                    "plan_name": "Targeted therapy",
                    "plan_details": "Encorafenib + cetuximab ± FOLFOX",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line systemic therapy",
                    "patient_subgroup": "HER2-amplified",
                    "plan_name": "HER2-targeted therapy",
                    "plan_details": "Trastuzumab + pertuzumab or trastuzumab-deruxtecan",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Subsequent-line therapy",
                    "patient_subgroup": "Biomarker-directed",
                    "plan_name": "Targeted options",
                    "plan_details": "KRAS G12C inhibitors (sotorasib/adagrasib) + anti-EGFR; TRK inhibitors (larotrectinib/entrectinib) for NTRK fusions",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Other regimen"
                }
            ]
        },
        {
            "staging_criteria": "Post-neoadjuvant therapy",
            "risk_group": "Complete clinical response (cCR)",
            "treatment_plans": [
                {
                    "treatment_line": "Non-operative management",
                    "patient_subgroup": "Organ preservation candidates",
                    "plan_name": "Watch-and-Wait surveillance",
                    "plan_details": "DRE/proctoscopy + MRI q3-6mo × 3yr; CT chest/abdomen q6-12mo × 5yr",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred option"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "dMMR/MSI-H: Ultra-hypermutated phenotype (TMB ≥50 mut/Mb); predicts response to immunotherapy",
            "POLE/POLD1 Mutation: Ultra-hypermutated phenotype (TMB ≥50 mut/Mb); indicates immunotherapy sensitivity",
            "RAS (KRAS/NRAS) Mutant: Confers resistance to anti-EGFR therapy",
            "BRAF V600E Mutation: Poor prognosis; sporadic if MLH1-deficient; requires targeted therapy",
            "HER2 Amplification: Occurs in 2-5% of CRC; causes resistance to anti-EGFR in RAS/BRAF wild-type",
            "NTRK Fusion: Rare (0.35%); enriched in dMMR tumors; indicates TRK inhibitor sensitivity",
            "Tumor Regression Grade (TRG): Post-treatment response predictor; TRG 0 (pCR) correlates with improved DFS/OS"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：直肠癌.txt"
}